Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer

NCT ID: NCT01741116

Last Updated: 2021-02-18

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 44 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-11-30
• Study Completion Date: 2016-10-31

Brief Summary

The aim of this study is to evaluate efficacy and safety of Dovitinib(TKI258) in patients with castration resistant prostate cancer after failure of docetaxel-based chemotherapy. Further correlative study for metabolic response using PET image and change in serum fibroblast growth factor 23(FGF23) will be conducted.

Detailed Description

Growth factor signals are important in carcinogenesis and progression of prostate cancer, and fibroblast growth factors (FGF) have important roles in this regard. FGF ligands (FGF1, -2, -6, -8, and -17) and FGF receptors (FGFR1 and FGFR4) have all shown to be significantly overexpressed in prostate cancer1-5. And, the recent studies have demonstrated that the critical roles of the FGF family members are mediated by the signaling between epithelial and stromal compartments, thus, promoting epithelial-mesenchymal transition (EMT)6,7. Moreover, a recent study has shown that FGF-2 is a mediator of second wave angiogenesis and tumor progression in men during the formation of castration-resistant tumors. Therefore, inhibition of signaling via FGF axis might be a viable strategy for the treatment of castration-resistant prostate cancer.

TKI258, an oral multitargeted receptor tyrosine kinase (RTK) inhibitor is known to potently inhibit the class III, IV, and V RTKs, showing biochemical 50 percent inhibitory concentration(IC50) values <20 nmol/L for VEGFRs (VEGFR-1, VEGFR-2, and VEGFR-3); the platelet-derived growth factor receptor-β (PDGFR-β); fibroblast growth factor receptors 1, 2, and 3 (FGFR-1,2,3); fetal liver tyrosine kinase receptor 3 (FLT-3); and KIT Ret, tyrosine kinase A (TrkA), and csf-1 RTKs. Due to the unique inhibitory activity on FGF pathways, TKI258 has shown significant activity in a variety of tumor xenograft models in athymic mice, including acute myeloid leukemia, multiple myeloma, and colon- and prostate-derived models9.

Castration-resistant prostate cancers (CRPC) are one of the challenges in oncology practice. Although there have been advances in chemotherapy10, new hormonal agents11, and immunotherapeutics12, patients in this subgroup still have limited life expectancy. Therefore, there is an urgent need to identify therapeutic targets and clinical development of target agents for the treatment of CRPC. For this end, sorafenib has been tested in multiple phase II studies earlier13-17; however, the clinical efficacy was very limited. The low efficacy of sorafenib might be partly explained by the lower potency in inhibition of RTKs. Considering nanomolar concentration range of IC50 for TKI258 compared with micromolar concentration for other multi-TKIs, the efficacy of TKI258 should be evaluated in CRPC patients.

Conditions

Hormone Refractory Prostate Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

TKI258, inhibitor of RTKs

Intervention: TKI258

Investigational drug, TKI258, will be administered to all of the patients after enrollments. Treatment will initially be administered as 28-day cycles as follows:

• Daily 500mg of TKI258 will be self-administered orally by the patient for 5 days, followed by 2 days of treatment off.

Group Type: EXPERIMENTAL

TKI258

Intervention Type: DRUG

Investigational treatment refers to TKI258 in this study Until Progression, unacceptable toxicity, withdrawal

Interventions

TKI258

Investigational treatment refers to TKI258 in this study Until Progression, unacceptable toxicity, withdrawal

Intervention Type: DRUG

Other Intervention Names

Dovitinib

Eligibility Criteria

Inclusion Criteria

• Patients with histologically confirmed progressive metastatic androgen-independent adenocarcinoma of the prostate with radiographic evidence of disease.
• No more than two previous cytotoxic chemotherapy
• Castration level of testosterone (< 50 ng/dl) achieved by orchiectomy or gonadotropin-releasing hormone(GnRH) agonist
• Eastern Cooperative Oncology Group(ECOG) performance status 0 - 2
• Finished any study drug or chemotherapy earlier than 4 weeks before the first administration of the study drug.
• Age ≥ 20 years old
• Patients must have the following laboratory values:

• Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
• Platelets ≥ 75 x 109/L
• Hemoglobin (Hgb) > 8 g/dL
• Serum total bilirubin: ≤ 1.5 x ULN
• alanine transaminase(ALT) and aspartate aminotransferase(AST) ≤ 2.0 x upper limit of normal(ULN) with or without liver metastases
• Serum creatinine ≤ 1.5 x ULN or serum creatinine >1.5 - 3 x ULN or 1.5 x ULN<serum creatinine < 3 x ULN, if calculated creatinine clearance (CrCl) is ≥ 30 mL/min using the Cockcroft-Gault equation, see formula below:

CrCl = [140-age (years)] x weight (kg) / [72 x serum Cr (mg/dL)] (if patient is female multiply the above by 0.85)

• Patients who give a written informed consent obtained according to local guidelines

Exclusion Criteria

Patients eligible for this study must not meet any of the following criteria

• Patients with known brain metastases or who have signs/symptoms attributable to brain metastases and have not been assessed with radiologic imaging to rule out the presence of brain metastases
• Patients with another primary malignancy within 3 years prior to starting study drug, with the exception of adequately treated in-situ carcinoma of the uterine cervix, basal or squamous cell carcinoma or non-melanomatous skin cancer

• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Korean Cancer Study Group

OTHER

Sponsor Role: lead

Responsible Party

Kyong-Hwa, Park

Korean Cancer Study Group

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Kyong Hwa Park, MD, phD

Role: PRINCIPAL_INVESTIGATOR

Korea University

Locations

Korean Cancer Study Group

Seoul, Chongro-ku, South Korea

Korea University Anam Hospital

Seoul, Seongbuk-gu, Inchon-ro, South Korea

Countries

South Korea

References

Dorkin TJ, Robinson MC, Marsh C, Bjartell A, Neal DE, Leung HY. FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. Oncogene. 1999 Apr 29;18(17):2755-61. doi: 10.1038/sj.onc.1202624.

Reference Type: BACKGROUND

PMID: 10348350 (View on PubMed)

Gnanapragasam VJ, Robinson MC, Marsh C, Robson CN, Hamdy FC, Leung HY. FGF8 isoform b expression in human prostate cancer. Br J Cancer. 2003 May 6;88(9):1432-8. doi: 10.1038/sj.bjc.6600875.

Reference Type: BACKGROUND

PMID: 12778074 (View on PubMed)

Heer R, Douglas D, Mathers ME, Robson CN, Leung HY. Fibroblast growth factor 17 is over-expressed in human prostate cancer. J Pathol. 2004 Dec;204(5):578-86. doi: 10.1002/path.1668.

Reference Type: BACKGROUND

PMID: 15538740 (View on PubMed)

Other Identifiers

GU11-05

Identifier Type: OTHER

Identifier Source: secondary_id

KCSG-GU11-05

Identifier Type: -

Identifier Source: org_study_id